Details
Stereochemistry | ACHIRAL |
Molecular Formula | C30H27N5O |
Molecular Weight | 473.5683 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC1=CC=C(C)C(NC(=O)C2=CC=C(NC3=NC4=C(C=CC=C4)C(=N3)C5=CC=CC=C5)C=C2)=C1
InChI
InChIKey=KLRRGBHZCJLIEL-UHFFFAOYSA-N
InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)
Molecular Formula | C30H27N5O |
Molecular Weight | 473.5683 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22177102 | https://www.ncbi.nlm.nih.gov/pubmed/23915072Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22177102 | https://www.ncbi.nlm.nih.gov/pubmed/23915072
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923
BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. BMS-833923 is an orally bioavailable Smoothened antagonist. BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. BMS-833923 is in phase II clinical trials for the treatment of chronic myeloid leukaemia.
Originator
Sources: http://adisinsight.springer.com/drugs/800027735
Curator's Comment: BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. # Exelixis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25670876 |
21.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01218477
Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24733827
BMS-833923 (10 uM) decreased cell proliferation of cholangiocellular carcinoma cell line (EGI-1) up to 89.4% compared to the control.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:17:37 GMT 2023
by
admin
on
Sat Dec 16 05:17:37 GMT 2023
|
Record UNII |
41J7ZJ239R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1059734-66-5
Created by
admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
|
PRIMARY | |||
|
57662985
Created by
admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
|
PRIMARY | |||
|
41J7ZJ239R
Created by
admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|